AR080074A1 - Naftiridinas sustituidas y su uso como medicamentos - Google Patents

Naftiridinas sustituidas y su uso como medicamentos

Info

Publication number
AR080074A1
AR080074A1 ARP110100305A AR080074A1 AR 080074 A1 AR080074 A1 AR 080074A1 AR P110100305 A ARP110100305 A AR P110100305A AR 080074 A1 AR080074 A1 AR 080074A1
Authority
AR
Argentina
Prior art keywords
alkyl
nr9r10
alkylene
hydrogen
individually selected
Prior art date
Application number
Other languages
English (en)
Inventor
Matthias Hoffmann
Guenter Linz
Gerhard Schaenzle
Andreas Schnapp
Georg Dahmann
Michael Philip Mazanetz
John Scott
Jasna Klicic
Edward Walker
Sandra Handschuh
Dennis Fiegen
Stephen P East
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR080074A1 publication Critical patent/AR080074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Composiciones farmacéuticas que contienen estos compuestos, y usos de los mismos. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) en la que R1 se selecciona entre -O-R3 o -NR3R4 donde R3 es alquilo C1-6 sustituido con R5 y R6 donde R5 se selecciona entre hidrogeno, alquilo C1-6 lineal o ramificado, alquenilo C2-6, -alquilen C1-6-O-alquilo C1-3, haloalquilo C1-3, donde R6 es un anillo X de formula (2); donde n es 0 o 1, donde es o bien un enlace sencillo o un doble enlace y donde A, B, D y E se seleccionan cada uno independientemente entre CH2, CH, C, N, NH, O o S y donde el anillo X se adjunta a la molécula mediante la posicion A, B, D o E, donde dicho anillo X puede estar opcionalmente sustituido con uno, dos o tres residuos seleccionados cada uno individualmente entre el grupo que consiste en -oxo, hidroxi, -alquilo C1-3, -haloalquilo C1-3, -O-alquilo C1-3, -alcanol C1-3 y halogeno, R4 se selecciona entre el grupo que consiste en hidrogeno y alquilo C1-6, R2 se selecciona entre el grupo que consiste en hidrogeno; arilo de 5 a 10 miembros; heteroarilo de 5 a 10 miembros que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S; heterociclo saturado o parcialmente insaturado de 5 a 10 miembros que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S; cicloalquilo saturado o parcialmente insaturado de 3 a 10 miembros, donde - en caso de que R2 no sea hidrogeno - dicho R2 puede estar opcionalmente sustituido con 1, 2, 3 o 4 residuos, cada uno individualmente seleccionado entre el grupo que consiste en hidrogeno, -oxo, halogeno, -alquilo C1-6, -alquenilo C2-6, -alquilen C1-6-COOH, -COOH, -CO-NR9R10, -alquilen C1-6-CO-NR9R10, -alquilen C1-6-NR9R10, -alquilen C1-6-CO-Q, -CO-Q, -alquilen C1-6-CO-NR9Q, -CO-NR9Q, -alquilen C1-6-NR11-CO-NR9R10, -alquilen C1-6-NR11-CO-Q, -alquilen C1-6-NR11-SO2R9, -alquilen C1-6-O-CO-R9, -alquilen C1-6-O-CO-NR9R10, -alquilen C1-6-O-R9, -alquilen C1-6-SO-NR9R10, -alquilen C1-6-SO2R9, -alquilen C1-6-SOR9, -alquinilen C1-6-O-R9, -alquinilen C1-6-Q, -alquinilen C1-6-NR9R10, arilo C5-10, -Q, -cicloalquilo C3-8, -O-R7, -O-alquilen C1-6-R7, -O-alquilen C1-6-O-R7, -haloalquilo C1-3, cianuro, -NR11R7, -NR11(alquilen C1-6-R7), -S(O)-alquilo C1-6, -SO2-alquilo C1-6, -S-alquilo C1-6, -SO2-NR9R10, -SO2-NR11Q, heteroarilo de 5 a 10 miembros que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S, -NR11-CO-R7 y -O-CO-R7, donde R7 se selecciona del grupo que consiste en hidrogeno; alquilo C1-6 lineal o ramificado; -haloalquilo C1-6; -alquilen C1-6-COOH; -alquilen C1-6-CO-NR9R10; -alquilen C1-6-CO-Q; -alquilen C2-6-NR11-CO-NR9R10; -alquilen C2-6-NR11-CO-Q; -alquilen C2-6-NR11-SO2R9; -alquilen C2-6-NR9R10; -alquilen C2-6-Q; -alquilen C2-6-O-CO-R9, -alquilen C2-6-O-CO-NR9R10, -alquilen C2-6-SO-NR9R10, -alquilen C2-6-SO2-R9, -alquilen C2-6-SO-R9, -SO2-R9, -SO-R9, -SO2-NR9R10, -SO2-NR11Q, -SO2-Q, -alquilen C1-6-O-R9 -CO-NR9R10, -CONR9Q, -CO-R9, -CO-Q, -alquilen C1-6-Q, -arilo C5-10, -Q, cicloalquilo saturado o parcialmente insaturado de 3 a 8 miembros; heteroarilo de 5 a 10 miembros que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S; -alquilen C1-6-heteroarilo, donde este heteroarilo tiene 5 a 10 miembros y comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S; donde - en caso de que R7 no sea hidrogeno - R7 puede estar opcionalmente sustituido con 1, 2 o 3 residuos R8 que se seleccionan individualmente entre el grupo que consiste en hidrogeno; -oxo; hidroxi; -alquilo C1-6; -haloalquilo C1-6; -NR9R10 , -Q, -NR9Q, cicloalquilo saturado o parcialmente insaturado de 3 a 6 miembros; donde - en caso de que R8 no sea hidrogeno - R8 puede estar opcionalmente sustituido con 1, 2 o 3 residuos seleccionados entre hidrogeno, -oxo, -hidroxi, -alquilo C1-6, halogeno, -haloalquilo C1-6, -O-alquilo C1-6, -alquilen C1-3-O-alquilo C1-3, donde cada uno de R9, R1° y R11 se selecciona individualmente uno de otro del grupo que consiste en hidrogeno, -alquilo C1-6, -cicloalquilo C3-8, -alquil C1-6-cicloalquilo C3-8 y fenilo, y donde cada Q se selecciona individualmente o bien de un heterociclo saturado o parcialmente insaturado de 5 a 10 miembros o de un heterociclo parcialmente insaturado que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O o S, o entre un heteroarilo de 5 a 10 miembros que comprende 1, 2 o 3 heteroátomos cada uno individualmente seleccionado entre N, O y S; donde Q está unido al resto de la molécula o bien mediante un átomo de carbono o mediante un átomo de nitrogeno, los N-oxidos de los compuestos anteriormente mencionados, particularmente los 1-naftiridinil-oxidos de los compuestos previamente mencionados, y las sales farmacéuticamente aceptables de los compuestos anteriormente mencionados.
ARP110100305 2010-01-29 2011-01-28 Naftiridinas sustituidas y su uso como medicamentos AR080074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10152159 2010-01-29

Publications (1)

Publication Number Publication Date
AR080074A1 true AR080074A1 (es) 2012-03-14

Family

ID=42272624

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100305 AR080074A1 (es) 2010-01-29 2011-01-28 Naftiridinas sustituidas y su uso como medicamentos

Country Status (18)

Country Link
US (2) US8969568B2 (es)
EP (1) EP2528915B1 (es)
JP (1) JP5629331B2 (es)
KR (1) KR20120125267A (es)
CN (1) CN102822172A (es)
AR (1) AR080074A1 (es)
AU (1) AU2011209274B8 (es)
BR (1) BR112012018865A2 (es)
CA (1) CA2786245A1 (es)
CL (1) CL2012001807A1 (es)
EA (1) EA201201052A1 (es)
IL (1) IL220553A0 (es)
MX (1) MX2012008533A (es)
NZ (1) NZ600857A (es)
TW (1) TW201139435A (es)
UY (1) UY33205A (es)
WO (1) WO2011092128A1 (es)
ZA (1) ZA201204793B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604049B2 (en) 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
JP5629331B2 (ja) 2010-01-29 2014-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及びｓｙｋキナーゼ阻害剤としてのその使用
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
CA2843022C (en) 2011-07-26 2019-09-24 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments
US20150307491A1 (en) * 2012-12-07 2015-10-29 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
CN104812753A (zh) * 2012-12-07 2015-07-29 和记黄埔医药（上海）有限公司 作为Syk抑制剂的取代吡啶并吡嗪类化合物
US9212178B2 (en) 2013-10-21 2015-12-15 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
CN110183440B (zh) 2014-03-19 2022-04-22 勃林格殷格翰国际有限公司 杂芳基syk抑制剂
WO2017042100A1 (en) 2015-09-11 2017-03-16 Boehringer Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
SI3364958T1 (sl) * 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114315747A (zh) * 2020-09-30 2022-04-12 山东润博生物科技有限公司 一种5,5-二甲基异噁唑烷-3-硫酮的制备方法
KR20220138655A (ko) * 2021-04-06 2022-10-13 주식회사 온코크로스 신장 질환의 예방 또는 치료용 화합물
KR20220138654A (ko) * 2021-04-06 2022-10-13 주식회사 온코크로스 당뇨병의 예방 또는 치료용 화합물
CN113735791A (zh) * 2021-10-14 2021-12-03 杭州欧晨科技有限公司 一种3-溴-5,5-二甲基-4,5-二氢异噁唑的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260759A (en) 1969-04-14 1981-04-07 Schering-Corporation Process for preparing 1-aminonaphthyridines
US3928367A (en) 1969-04-14 1975-12-23 Schering Corp 1-Amino naphthyridines
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US4115395A (en) 1975-11-12 1978-09-19 Schering Corporation 1-Aminonaphthyridines
DE3027619A1 (de) 1979-07-25 1981-02-19 Sandoz Ag 6-alkyl-7-phenyl-1,6-naphtyradin- 5(6h)-on-derivate
US4329349A (en) 1979-07-25 1982-05-11 Sandoz, Inc. 6-C1-4 Alkyl-7-phenyl or substituted phenyl-1,6-naphthyridine-5(6H)-ones
WO1999018077A1 (fr) 1997-10-02 1999-04-15 Eisai Co., Ltd. Derives de pyridine condenses
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
ME00243B (me) 2000-10-12 2011-05-10 Boehringer Ingelheim Pharma Kristalni monohidrat, postupak za njegovo pripremanje i njegova primena za pripremanje lijeka
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
WO2003005769A2 (de) * 2001-07-04 2003-01-16 Braincom Ag Flächenheizung, verfahren zu deren herstellung und heizbarer gegenstand sowie sitzbelegungserkennung, sitz damit und sitzbelegungserkennungsverfahren
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
CN1863774B (zh) 2003-10-08 2010-12-15 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US7452887B2 (en) 2004-06-04 2008-11-18 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
AU2007309279B2 (en) 2006-10-20 2011-03-24 Irm Llc Compositions and methods for modulating c-kit and PDGFR receptors
US8236950B2 (en) * 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
PL2118074T3 (pl) * 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
KR20090031333A (ko) 2007-09-21 2009-03-25 주식회사 엘지생명과학 신규한 베타-세크리타제 저해용 화합물
CN101808999B (zh) 2007-09-27 2013-02-13 弗·哈夫曼-拉罗切有限公司 用作5ht5a受体拮抗剂的喹啉衍生物
US8604049B2 (en) 2008-08-05 2013-12-10 Boehringer Ingelheim International Gmbh 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments
JP2011529932A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
FR2949465B1 (fr) 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
JP5629331B2 (ja) 2010-01-29 2014-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及びｓｙｋキナーゼ阻害剤としてのその使用
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CA2843022C (en) 2011-07-26 2019-09-24 Boehringer Ingelheim International Gmbh Substituted quinolines and their use as medicaments
JP2014521616A (ja) 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体

Also Published As

Publication number Publication date
JP2013518073A (ja) 2013-05-20
AU2011209274B8 (en) 2015-08-13
CA2786245A1 (en) 2011-08-04
US20120028939A1 (en) 2012-02-02
IL220553A0 (en) 2012-08-30
BR112012018865A2 (pt) 2016-04-12
US8969568B2 (en) 2015-03-03
MX2012008533A (es) 2012-08-31
CN102822172A (zh) 2012-12-12
UY33205A (es) 2011-08-31
TW201139435A (en) 2011-11-16
US20150126503A1 (en) 2015-05-07
WO2011092128A1 (en) 2011-08-04
AU2011209274A8 (en) 2015-08-13
NZ600857A (en) 2014-06-27
ZA201204793B (en) 2013-02-27
EP2528915B1 (en) 2015-10-28
AU2011209274A1 (en) 2012-07-19
US9187478B2 (en) 2015-11-17
EA201201052A1 (ru) 2013-02-28
JP5629331B2 (ja) 2014-11-19
AU2011209274B2 (en) 2015-07-16
EP2528915A1 (en) 2012-12-05
CL2012001807A1 (es) 2012-10-12
KR20120125267A (ko) 2012-11-14

Similar Documents

Publication Publication Date Title
AR080074A1 (es) Naftiridinas sustituidas y su uso como medicamentos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
NI200900042A (es) Nuevo derivados de dismetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
AR078776A1 (es) Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo

Legal Events

Date Code Title Description
FB Suspension of granting procedure